|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2007-4-10
|
|
pubmed:abstractText |
Bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor (VEGF), has been given via intravitreal injection as an off-label therapy for both neovascular age-related macular degeneration and for macular edema secondary to retinal vascular disease. The authors describe three patients with macular edema secondary to retinal venous occlusion whose edema initially responded to intravitreal bevacizumab but subsequently recurred in excess of that observed before treatment.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0275-004X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
27
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
426-31
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:17420693-Aged,
pubmed-meshheading:17420693-Angiogenesis Inhibitors,
pubmed-meshheading:17420693-Antibodies, Monoclonal,
pubmed-meshheading:17420693-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:17420693-Female,
pubmed-meshheading:17420693-Fluorescein Angiography,
pubmed-meshheading:17420693-Humans,
pubmed-meshheading:17420693-Injections,
pubmed-meshheading:17420693-Macular Edema,
pubmed-meshheading:17420693-Male,
pubmed-meshheading:17420693-Middle Aged,
pubmed-meshheading:17420693-Recurrence,
pubmed-meshheading:17420693-Retinal Vein Occlusion,
pubmed-meshheading:17420693-Tomography, Optical Coherence,
pubmed-meshheading:17420693-Vascular Endothelial Growth Factor A,
pubmed-meshheading:17420693-Visual Acuity,
pubmed-meshheading:17420693-Vitreous Body
|
|
pubmed:articleTitle |
Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease.
|
|
pubmed:affiliation |
Vitreous-Retina-Macula Consultants of New York, and LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear and Throat Hospital, New York, New York 10022, USA.
|
|
pubmed:publicationType |
Journal Article,
Case Reports,
Research Support, Non-U.S. Gov't
|
